Dupixent Den europeiske union - norsk - EMA (European Medicines Agency)

dupixent

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenter for dermatitt, unntatt kortikosteroider - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Alutard SQ Bjørk 100000 SQ-E/ ml Norge - norsk - Statens legemiddelverk

alutard sq bjørk 100000 sq-e/ ml

alk-abelló as - allergen av bjørkepollen - injeksjonsvæske, suspensjon - 100000 sq-e/ ml

Alutard SQ Bjørk Norge - norsk - Statens legemiddelverk

alutard sq bjørk

alk-abelló as - allergen av bjørkepollen - injeksjonsvæske, suspensjon - 1000 sq-e/ ml / 100 sq-e/ ml / 100000 sq-e/ ml / 10000 sq-e/ ml

Alutard SQ Bjørk 10000 SQ-E/ ml Norge - norsk - Statens legemiddelverk

alutard sq bjørk 10000 sq-e/ ml

alk-abelló as - allergen av bjørkepollen - injeksjonsvæske, suspensjon - 10000 sq-e/ ml

Alutard SQ Timotei 10000 SQ-E/ ml Norge - norsk - Statens legemiddelverk

alutard sq timotei 10000 sq-e/ ml

alk-abelló as - allergen av timotei - injeksjonsvæske, suspensjon - 10000 sq-e/ ml

Alutard SQ Timotei Norge - norsk - Statens legemiddelverk

alutard sq timotei

alk-abelló as - allergen av timotei - injeksjonsvæske, suspensjon - 1000 sq-e/ ml / 100000 sq-e/ ml / 10000 sq-e/ ml / 100 sq-e/ ml

Alutard SQ Timotei 100000 SQ-E/ ml Norge - norsk - Statens legemiddelverk

alutard sq timotei 100000 sq-e/ ml

alk-abelló as - allergen av timotei - injeksjonsvæske, suspensjon - 100000 sq-e/ ml

Betnovat 0.1 % Norge - norsk - Statens legemiddelverk

betnovat 0.1 %

glaxosmithkline as - betametasonvalerat - krem - 0.1 %

Betnovat 1 mg/ ml Norge - norsk - Statens legemiddelverk

betnovat 1 mg/ ml

glaxosmithkline as - betametasonvalerat - liniment, oppløsning - 1 mg/ ml

Betnovat 0.1 % Norge - norsk - Statens legemiddelverk

betnovat 0.1 %

glaxosmithkline as - betametasonvalerat - salve - 0.1 %